Completed PHASE1 INTERVENTIONAL 2-arm NCT00716014

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita

A Single-Center, Placebo-Controlled, Rising Dose to Tolerance and Safety Study of TD101, an siRNA Designed for Treatment of Pachyonychia Congenita

Sponsor: Pachyonychia Congenita Project

Conditions Pachyonychia Congenita

Interventions Normal saline (placebo) TD101

Updated 6 times since 2017 Last updated: Nov 18, 2008 Started: Jan 31, 2008 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Pachyonychia Congenita, this trial is completed. The trial is conducted by Pachyonychia Congenita Project and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pachyonychia Congenita Project

Data source: Pachyonychia Congenita Project

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salt Lake City, United States